Voyager Therapeutics, Inc.
Voyager Reports Third Quarter 2026 Financial and Operating Results
- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment -
Company newsroom
NASDAQ:VYGR
1 releases
- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment -